ÂÜÀòÂÒÂ×

Dr. James Gulley brings over 20 years of leadership experience in the oncology field, serving currently as Co-Director of the newly formed Center for Immuno-Oncology (CIO) at the National Cancer Institute (NCI), part of the National Institutes of Health. The work he oversees at the CIO concentrates on focusing the immune response through vaccines or adoptive cellular therapy for solid tumors. He was instrumental in the clinical development of multiple vaccines including PROSTVAC, from the first-in-human studies at the CCR through a completed phase 3 clinical trial. He currently oversees new efforts in synthetic biology with cell therapy-based approaches including TCR engineered T-cells, CAR-T cells and engineered NK cells. Dr. Gulley has been the recipient of many honors and awards; most recently including the Hubert H. Humphrey Award for Service to America, the Award NCI Director’s Group Award, and the SITC Collaborator Award. He earned his PhD and MD at Loma Linda University. He completed his residency in Internal Medicine at Emory University, followed by a fellowship in Medical Oncology at the National Cancer Institute.